Prostate Cancer – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of prostate cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s prostate cancer forecast will answer the following questions:
- Of all people diagnosed with prostate cancer, how many in each country of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of prostate cancer over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 41 prostate cancer patient populations, as follows:
- Diagnosed incident cases of N0M0 low-risk disease.
- Diagnosed incident cases of N0M0 intermediate-risk disease.
- Diagnosed incident cases of N0M0 high-risk disease.
- Diagnosed incident cases of N1M0 disease.
- Diagnosed incident cases of NxM1 disease.
- Newly diagnosed low- / intermediate-risk (hormone-sensitive) drug-treated disease.
- Newly diagnosed high-risk / N1M0 (hormone-sensitive) drug-treated disease.
- Newly diagnosed metastatic (hormone-sensitive) non-drug-treated disease.
- Diagnosed drug-treatable prevalent cases.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Prostate Cancer - Epidemiology - Emerging Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of prostate cancer)
- Diagnosed incident cases
- TNM stage and NCCN risk category
- Recurrent incidence of prostate cancer
- Diagnosed prevalent cases
- Drug-treatable populations
- Drug-treated populations
- Risk / protective factors applied to disease forecast models
- Reference materials
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.